Skip to main content
Log in

Coexistence of Graves’ disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels

  • Case Report
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Struma ovarii is the most common monodermal ovarian teratoma and consists mainly of thyroid tissue. Only 5% of patients with this tumor have features of hyperthyroidism. The pathophysiology of hyperthyroidism in struma ovarii is not clear. Case: We describe a case of benign struma ovarii, presenting with the clinical features of an ovarian cancer: large complex pelvic mass, large amount of ascites and markedly elevated CA-125 serum levels. The patient was initially treated for Graves’ disease, on the basis of ultrasonographic, laboratoristic and scintigraphic evidence. The resistance to the medical treatment led to thyroidectomy. After surgery the hyperthyroidism persisted and, suddenly, the patient presented ascites. A large pelvic mass was then diagnosed which, at the pathologic examination, was diagnosed as a struma ovarii. Conclusion: The struma ovarii always has to be considered when a pelvic mass is associated with features of hyperthyroidism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bethune M, Quinn M, Rome R. Struma ovarii presenting as acute pseudo-Meigs syndrome with an elevated CA 125 level. Aust N Z J Obstet Gynaecol 1996, 36: 372–3.

    Article  CAS  PubMed  Google Scholar 

  2. Thomas RD, Batty VB. Metastatic malignant struma ovarii. Two case reports. Clin Nucl Med 1992, 17: 577–8.

    CAS  Google Scholar 

  3. Rosenblum NG, LiVolsi VA, Edmonds PR, Mikuta JJ. Malignant struma ovarii. Gynecol Oncol 1989, 32: 224–7.

    Article  CAS  PubMed  Google Scholar 

  4. Amr SS, Hassan AA. Struma ovarii with pseudo-Meigs’syndrome. Eur J Obstet Gynecol Reprod Biol 1994, 55: 205–8.

    Article  CAS  PubMed  Google Scholar 

  5. Ciccarelli A, Valdes-Socin H, Parma J, et al. Thyrotoxic adenoma followed by atypical hyperthyroidism due to struma ovarii: clinical and genetic studies. Eur J Endocrinol 2004, 150: 431–7.

    Article  CAS  PubMed  Google Scholar 

  6. Kung AWC, Ma JTC, Wang C, Young RTT. Hyperthyroidism during pregnancy due to coexistence of struma ovarii and Graves’disease. Postgrad Med J 1990, 66: 132–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Ropars A, Takorabet L, Marion S, Charrerire J. One Monoclonal antibody to human thyrotropin (TSH) receptor agonist of TSH hormone stimulates the proliferation of human thyroid cells. Cell Immunol 1995, 161: 262–9.

    Article  CAS  PubMed  Google Scholar 

  8. Wilders-Truschnig MM, Drexhage HA, Leb G, et al. Chromatoghaphically purified immunoglobulin G of endemic and sporadic goiter patients stimulates FRTL5 cell growth in a mitotic arrest assay. J Clin Endocrinol Metab 1990, 70: 444–52.

    Article  CAS  PubMed  Google Scholar 

  9. Timmerman D, Moerman P, Vergote I. Meigs’ syndrome with elevated serum CA 125 levels: two case report and review of the literature. Gynecol Oncol 1995, 59: 405–8.

    Article  CAS  PubMed  Google Scholar 

  10. Szyfelbein YM, Young RH, Scully RE. Struma ovarii simulating ovarian tumours of other types. A report of 30 cases. Am JSurgPathol 1995, 19: 21–9.

    CAS  Google Scholar 

  11. Huh JJ, Montz FJ, Bristow RE. Struma ovarii associated with pseudo-Meigs’ syndrome and elevated serum CA 125. Gynecol Oncol 2002, 86: 231–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to V. D. Mandato.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guida, M., Mandato, V.D., Di Spiezio Sardo, A. et al. Coexistence of Graves’ disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels. J Endocrinol Invest 28, 827–830 (2005). https://doi.org/10.1007/BF03347575

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347575

Key-words

Navigation